Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Optimizing combination chemotherapy by controlling drug ratios.

Lawrence D Mayer1, Andrew S Janoff

  • 1Celator Pharmaceuticals, 1779 West Seventy-fifth Avenue, Vancouver BC V6P 6P2. lmayer@celatorpharma.com

Molecular Interventions
|September 11, 2007
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

CPX-351: a nanoscale liposomal co-formulation of daunorubicin and cytarabine with unique biodistribution and tumor cell uptake properties.

International journal of nanomedicine·2019
Same author

A phase 2 study to assess the pharmacokinetics and pharmacodynamics of CPX-351 and its effects on cardiac repolarization in patients with acute leukemias.

Cancer chemotherapy and pharmacology·2019
Same author

Improving combination cancer therapy: the CombiPlex<sup>®</sup> development platform.

Future oncology (London, England)·2018
Same author

CPX-351 exhibits potent and direct ex vivo cytotoxicity against AML blasts with enhanced efficacy for cells harboring the FLT3-ITD mutation.

Leukemia research·2016
Same author

Efficacy of CPX-351, (cytarabine:daunorubicin) liposome injection, against acute lymphoblastic leukemia (ALL) xenograft models of the Pediatric Preclinical Testing Program.

Pediatric blood & cancer·2014
Same author

Nanoscale particulate systems for multidrug delivery: towards improved combination chemotherapy.

Therapeutic delivery·2014

Optimizing cancer chemotherapy involves precise drug ratios. Nanotechnology enables controlled delivery of synergistic drug combinations, improving treatment efficacy and reducing toxicity for various diseases.

Area of Science:

  • Oncology
  • Nanomedicine
  • Pharmacology

Background:

  • Standard chemotherapy often maximizes individual drug doses, risking toxicity without guaranteeing optimal efficacy.
  • Drug interactions can be synergistic or antagonistic depending on their ratios, suggesting lower doses may be more effective.
  • Traditional combination therapies struggle to maintain specific drug ratios in vivo.

Purpose of the Study:

  • To explore the potential of a ratiometric approach in combination chemotherapy.
  • To leverage advances in nanotechnology for controlled drug delivery.
  • To enhance the efficacy of anticancer treatments by exploiting synergistic drug ratios.

Main Methods:

  • Utilizing nano-scale drug delivery vehicles for precise drug ratio control.

Related Experiment Videos

  • Translating in vitro synergistic drug ratio data into in vivo therapeutic strategies.
  • Developing methods to maintain controlled drug ratios post-administration.

    • Main Results:

    • Demonstrated the feasibility of using nanotechnology to control drug ratios in combination therapy.
    • Showcased the potential for synergistic drug interactions to be effectively exploited.
    • Indicated that precise ratio control can overcome antagonistic effects seen with conventional dosing.

    Conclusions:

    • A ratiometric approach to combination chemotherapy, enabled by nanodelivery systems, offers a novel strategy.
    • This method can improve the effectiveness of existing and future cancer treatments.
    • Exploiting synergistic drug ratios holds promise for enhancing therapeutic outcomes across diseases.